

# NIH funding opportunities

16 Nov 2023 (#36)



**Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.**



See all Important Notices, Parent Announcements and Notice of Special Interest below

**Plan your application. Before starting your application attend**

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

**To prepare an application can take *4-18 months*.**

**From submission to receiving a Notice of Award can take *10 months***

## Important Notices

**[NOT-OD-24-010](#) Simplified Review Framework for NIH Research Project Grant Applications.** This notice announces a new framework for the peer review of most research project grant (RPG) applications beginning with submissions for due dates on or after January 25, 2025. The simplified review framework is expected to better focus peer reviewers on the key questions needed to assess the scientific and technical merit of proposed research projects: “*Should the proposed research project be conducted?*” “*Can the proposed research project be conducted?*”

**[NOT-AG-23-065](#) Notice of Intent to Publish a Funding Opportunity Announcement for Geroscience Course (R25 Independent Clinical Trial Not Allowed).** The purpose of this Notice is to inform potential applicants that the National Institute on Aging (NIA) and the Office of Dietary Supplements (ODS) intend to reissue the Notice of Funding Opportunity (NOFO) [PAR-22-214](#), “Geroscience Course (R25 Independent Clinical Trial Not Allowed).” When reissued, this NOFO will solicit Research Education Program (R25) applications to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral, and clinical research needs. Additionally, this NOFO will seek to increase general awareness of geroscience by taking a multidisciplinary approach to support educational activities with a primary focus on the development and integration of basic, applied, translational, and clinical topics in geroscience. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. First Estimated Application Due Date: February 14, 2024.

**[NOT-CA-23-096](#) Notice of Intent to Publish a Funding Opportunity Announcement for National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required).** The National Cancer Institute (NCI) intends to reissue the NCI's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) Notice of Funding Opportunity (NOFO), which will support research projects that propose early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the NCI's Division of Cancer Treatment and Diagnosis (DCTD), and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Interested applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website

to learn more about the various program goals, research priorities, and strategies developed to fight cancer. The NOFO is a re-issuance of [PAR-21-033](#). First Estimated Application Due Date: February 05, 2024.

**[NOT-DK-24-001](#) Notice of Intent to Publish a Funding Opportunity Announcement for Cardiovascular Repository – Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed).** The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on the cardiovascular complications of type 1 diabetes (T1D) as part of the NIH Cardiovascular Repository for T1D (CaRe-T1D). Cardiovascular disease (CVD) is the leading cause of death for individuals with T1D and significantly shorten their lives. [CaRe-T1D](#) was initiated with the goal of establishing a biorepository of human CV tissue and a scientific consortium to advance and support discovery and mechanistic research that increase the understanding of CVD in T1D. The first phase launched the biorepository and now in the second phase investigative teams will be added to form a consortium with the biorepository serving as the Coordinating Center (CC). The goal of the new initiative is to attract investigative teams with complementary interests and expertise who will leverage these resources through individual and collaborative studies to advance our knowledge of the pathogenesis of CVD in T1D. First Estimated Application Due Date: April 11, 2024.

## Parent Announcements

**[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates  
*Expiration Date: May 8, 2023. Modified Expiration Date: May 8, 2024*

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest

**[NOT-AI-23-074](#) Administrative Supplement to Support Research Opportunities at NIAID Intramural Facilities.** This NOSI is specifically designed to promote partnerships between eligible NIAID-funded extramural research investigators and NIAID intramural research investigators (i.e., those conducting research within the laboratories and clinics of NIAID). The intent is to foster and stimulate basic, translational, and applied research that will advance scientific discovery and engage extramural researchers working collaboratively in the areas of immunology, infectious diseases, and allergy. This NOSI will provide funding to NIAID-supported extramural research investigator to travel to NIAID laboratories for a short duration to perform research in partnership with a host intramural research investigator. Applicants must include a letter of support from the PD/PI of the NIAID intramural research laboratory where the extramural investigator will be conducting research. Application Due Date: February 2, 2024 by 5:00 PM local time of applicant organization. Only recipients of awards funded under the following activity codes are eligible: R15, R16, R21, R03. The project period and budget period may not exceed one year, and on-site collaborations may be limited to approx. three months. Budget requests must not exceed \$50,000 in direct costs.

**[NOT-CA-23-092](#) Research Projects to Develop Oncoaging Models for Cancer Research.** Through this NOSI, the National Cancer Institute (NCI) invites applications for projects to establish new or to improve existing models that recapitulate cancer development, progression and treatment response in the context of age-related biological changes, and to apply these models in basic and translational cancer research. The “oncoaging” models established through this NOSI are expected to facilitate research into the underlying biology of aging mechanisms which modify cancer susceptibility and progression, and/or alter the trajectory of therapeutic responses. This knowledge is necessary to inform novel cancer therapies for the older population. Responsive projects will be focused on establishing and characterizing cancer models, that consider aging as a risk factor, demonstrating how robustly they recapitulate human biology, assessing their clinical relevance, and validating their utility in mechanistic studies and/or translational research. This notice applies to due dates on or after February 5, 2024, and subsequent receipt dates through July 31, 2027.

[NOT-HL-23-117](#) **Palliative Care in the Care Continuum among Persons with Serious Heart, Lung, Blood and Sleep (HLBS) Diseases and their Caregivers.** The purpose of this NOSI is to highlight NHLBI-specific needs, encourage collaboration between heart, lung, blood and sleep (HLBS) and palliative care (PC) researchers, and continue to inform the research community of NHLBI interest in palliative care research. This NOSI seeks palliative care studies, including ancillary studies to ongoing clinical research studies. Studies addressing efficacy, effectiveness, dissemination and implementation research as well as studies seeking to understand and address barriers to incorporating PC early in the care continuum are encouraged. Applicants must select the IC and associated NOFO to use for submission of an application in response to the NOSI. The selection must align with the IC requirements listed in order to be considered responsive to that NOFO. This notice applies to due dates on or after February 5, 2024 and subsequent receipt dates through January 7, 2027

## Notice of Funding Opportunity (NOFO)

1. [PAR-24-045](#) **Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed).** The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to further understanding of the developmental trajectories of late talking children by leveraging existing data and creating open and shared data resources to aid in identifying patterns and predictors of developmental outcomes in late talking children, and exploring potential underlying mechanisms, risk factors, and sequelae.

**Due dates:** February 07, 2024, July 19, 2024, November 19, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. These direct cost caps are exclusive of facilities and administrative costs of consortia, when applicable.

2. [PAR-24-046](#) **Information and Practice Needs Relevant to Late Talking Children (R21 Clinical Trial Not Allowed).** The National Institutes of Health (NIH) Tackling Acquisition of Language in Kids (TALK) initiative seeks to support activities to better understand early language learning and delay. NIH TALK invites applications for research projects that aim to better understand the information and practice needs of caregivers, professionals, and other invested parties who support late talking children and to determine whether those needs are being effectively met. Community engaged research combined with rigorous qualitative research and diverse research teams are needed to enrich our understanding of how to get state-of-the-science information and practice to those who need it most to guide decisions about late talking children.

**Due dates:** February 07, 2024, July 19, 2024; November 19, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in a single year. These direct cost caps are exclusive of facilities and administrative costs of consortia, when applicable.

3. [PAR-24-051](#) **NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required).** The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This NOFO supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this NOFO, not require FDA oversight, not an NIH defined Phase III Clinical Trial, have low risks to subjects, and intends to gather scientific data/evidence to inform subsequent studies. This NOFO also supports low risk trials determined to be Basic Science Experimental Studies involving Humans ([BESH](#)). These studies fall within the NIH definition of a clinical trial and meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application.

**Due dates:** February 05, 2024 through to January 07, 2027. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date. **Budget:** Application budgets should be less than \$500,000 in direct costs in any year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**4. [RFA-CA-24-006](#) Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional).** Through this NOFO, the National Cancer Institute intends to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such as multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and KSHV inflammatory cytokine syndrome (KICS), or ameliorate the severity of disease. A therapeutic KSHV vaccine could be helpful in preventing or treating KSHV disease in people already infected with KSHV. The U01 research projects funded through this NOFO will form a cooperative group, the KSHV Vaccine Development Consortium (KVDC).

**Due dates:** December 21, 2023; December 04, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** NCI intends to commit an estimated total of \$3,000,000 in each FY (2024 and 2025) to fund 3 to 4 awards for each receipt date. It is anticipated that most application budgets should not exceed \$500,000 direct costs per year. However, with a strong justification, a budget can be up to \$750,000 direct costs per year. Application budgets should reflect the actual needs of the proposed project. For any question, applicants are encouraged to contact NCI Program Official(s) listed in Section VII of this NOFO. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**5. [RFA-DA-24-030](#) Applying Imaging Pipelines for Spatial Characterization of Cellular Interactions in HIV-related CNS Pathology and/or Substance Use (R61/R33 Clinical Trial Not Allowed).** This NOFO aims to support the development and application of innovative ex-vivo imaging technologies, along with necessary coordinated pipelines encompassing tissue procurement, histological processing and computation to enable spatial analysis and in situ molecular annotation of cell populations involved in central nervous system (CNS) HIV infection, persistence, and neuropathogenesis. The pipelines developed and validated during the R61 phase should be applicable to freshly collected or banked CNS tissues with well-preserved structure (whole brains, slices or explants) from humans or animal models. The utility of the pipelines should be demonstrated during the R33 phase, through test-cases investigating intercellular communication mechanisms in HIV-associated neurocognitive disorders (HAND), antiretroviral therapy (ART) response and/or substance use.

**Due dates:** February 08, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** NIH intends to fund an estimate of up to five awards, corresponding to a total of \$3 M for fiscal year 2024. Application direct costs are limited to \$300,000 during each year of the R61 phase and \$400,000 during each year of the R33 phase. The maximum period of the combined R61 and R33 phases is 5 years, with up to 3 years for the R61 phase and up to 2 years for the R33 phase. The scope of the proposed project should determine the requested project period.

**6. [RFA-DA-25-013](#) Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed).** The goal of this NOFO is to encourage research to explore mechanisms of inflammasome activation and their link to neurocognitive disorder (NCD) and immune function in people with HIV and substance use disorders (SUDs). This NOFO supports studies to (1) elucidate the role and the underlying mechanisms of inflammasomes in virus and drug-induced immune activation, (2) identify molecular markers associated with inflammasome pathways in NCD and 3) illuminate the cellular and tissue microenvironments that influence inflammasomes in HIV-1 infection or disease progression among individuals with SUD. Overall goal of this program is to facilitate translation of inflammasome research findings into therapeutic tools that improve clinical outcomes in people with HIV.

**Due dates:** March 13, 2024; March 13, 2025 by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000, and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is two years.

**7. [RFA-DA-25-012 Targeting Inflammasomes in HIV and Substance Use \(R01 Clinical Trial Not Allowed\)](#).** The goal of this NOFO is to encourage research to explore mechanisms of inflammasome activation and their link to neurocognitive disorder (NCD) and immune function in people with HIV and substance use disorders (SUDs). This NOFO supports studies to (1) elucidate the role and the underlying mechanisms of inflammasomes in virus and drug-induced immune activation, (2) identify molecular markers associated with inflammasome pathways in NCD and 3) illuminate the cellular and tissue microenvironments that influence inflammasomes in HIV-1 infection or disease progression among individuals with SUD. Overall goal of this program is to facilitate translation of inflammasome research findings into therapeutic tools that improve clinical outcomes in people with HIV.

**Due dates:** March 13, 2024; March 13, 2025. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** NIDA intends to support up to four awards for [RFA-DA-25-012](#) and [RFA-DA-25-013](#), corresponding to a total of \$2,000,000 in FY 2025. Future year amounts will depend on annual appropriations. Application budgets are limited to \$500,000 direct costs per year and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

<b>Faculty of Medicine and Health Sciences Research &amp; Internationalisation Development &amp; Support (RIDS) &amp; Grants Management Office (GMO) 009 K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.</b>	<b>Stellenbosch Campus Division for Research Development (DRD) 2041 Krotoa Building, Ryneveld Street</b>
<b>Enquiries: <a href="mailto:fmhsgmo@sun.ac.za">fmhsgmo@sun.ac.za</a></b>	<b>Enquiries: <a href="mailto:research@sun.ac.za">research@sun.ac.za</a></b>
<b>Add "Interest in NIH opportunity" in the subject line. Add the notice number in the text of the email.</b>	